Related Experiment Video
Updated: Mar 20, 2026

Laboratory Production of Biofuels and Biochemicals from a Rapeseed Oil through Catalytic Cracking Conversion
Published on: September 2, 2016
The introduction of high-purity products in Canada
1Transfusion Service, Vancouver Hospital & Health Sciences Centre, Vancouver, British Columbia, Canada,Canadian Blood Agency, Ottawa, Ontario, Canada.
Insights
Canada transitioned to high-purity coagulation products in 1993, increasing costs but enabling practice monitoring. A collaborative working group effectively evaluated this product conversion and its impact.
Area of Science:
- Hematology
- Pharmacoeconomics
- Public Health Policy
Background:
- In October 1993, Canada adopted high-purity coagulation products (recombinant or purified factor concentrates) for managing coagulation deficiencies.
- This shift led to a significant cost increase of approximately $30 million (40%) for the national inventory.
Purpose of the Study:
- To monitor the impact of introducing new high-purity coagulation products.
- To evaluate long-term outcomes including inhibitor formation, prophylaxis, immune status, and thrombosis incidence.
- To develop clinical practice guidelines for Hemophilia and Von Willebrand's Disease.
Main Methods:
- Establishment of a regular meeting forum for stakeholders (recipients, treaters, distributor, funders).
- Implementation of a continuous usage monitoring system managed by the Canadian Blood Agency.
- Inclusion of specific outcome studies by the Association of Hemophilia Clinic Directors of Canada.
Main Results:
- Early identification of practice trends and rationales for unexpected product use.
- Facilitation of planning and funding adjustments based on monitored data.
- Effective evaluation of the conversion to new products and their national impact.
Conclusions:
- The collaborative working group under the Canadian Blood Agency was effective in evaluating the product conversion.
- The monitoring system provided early insights into practice trends and resource utilization.
- This model can inform future endeavors in managing high-purity coagulation products.
Abstract:
In October 1993, the Canadian Blood Agency, the agent for the provinces/territories in Canada, agreed to the introduction of high-purity coagulation products, either recombinant or highly purified factor concentrates, for the management of coagulation deficiencies. This represented a cost increase of approximately $30 million (40%) for the national coagulation product inventory. Representatives of the relevant recipients of the products, some of the treaters, the distributor and the funders met on a regular basis in order to monitor the impact of these new products. The Association of Hemophilia Clinic Directors of Canada also agreed to include some specific outcome studies over a longer period of time to include evaluation of inhibitor formation, prophylaxis regimens, immune status and the incidence of thrombosis. The 'Hemophilia and Von Willebrand's Disease' clinical practice guidelines were also developed under their auspices. A usage monitoring system has been implemented and has been continuously managed by the Canadian Blood Agency. This resulted in trends of practice and rationales for unexpected use being identified early for planning and funding purposes. The Working Group set up under the auspices of the Canadian Blood Agency was an effective vehicle to evaluate the conversion and the impact of these new products in the country and can serve as a model for future endeavours.
Related Concept Videos
High-Performance Liquid Chromatography: Introduction
In HPLC, two phases play a critical role in the separation process:
Detergent Purification of Membrane Proteins
Chromatography: Introduction
The phase in which the compounds linger or on which the compounds adsorb is called the stationary phase, whereas the mobile phase is the solvent that carries the solutes to be analyzed. In traditional column chromatography, the mixture flows through the stationary phase, and the compounds partition between the stationary and mobile phases...
Production of Pharmaceuticals
Inductively Coupled Plasma–Mass Spectrometry (ICP–MS): Overview
Gas Chromatography–Mass Spectrometry (GC–MS)
A gas chromatograph consists of a long, narrow capillary column with a polysiloxane coating on the inner wall....

![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)